Get started
Work

P1.01-21 Safety of Durvalumab Retreatment in Advanced NSCLC Patients Who Progressed Following Initial Disease Control In ATLANTIC

Year: 2018
Type: article
DOI: 10.1016/j.jtho.2018.08.577
Authors: M. Garassino, B.C. Cho, J. Kim, J. Mazieres, J. Vansteenkiste, H. Lena, J. Corral, J. Gray, J. Powderly, C. Chouaid, P. Bidoli, P. Wheatley-Price, K. Park, R. Soo, Y. Huang, C. Wadsworth, P. Dennis, N. Rizvi
Institutions: Fondazione IRCCS Istituto Nazionale dei Tumori, Yonsei University, Yonsei University Health System, CHA University Bundang Medical Center, CHA University, Centre Hospitalier Universitaire de Toulouse, Universitair Ziekenhuis Leuven, KU Leuven, Hôpital Pontchaillou, Centre Hospitalier Universitaire de Rennes, Hospital Universitario Virgen del Rocío, Moffitt Cancer Center, Carolina BioOncology Institute, Hôpital Intercommunal de Créteil, Azienda Ospedaliera San Gerardo, University of Ottawa, Ottawa Hospital Research Institute, Samsung Medical Center, Sungkyunkwan University, National University Cancer Institute, Singapore, AstraZeneca (United States), AstraZeneca (United Kingdom), Columbia University Irving Medical Center
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: bronze
OpenAlex ID: W2898526365
FWCI: 0.085
Cites:
Cited by: 1
Related to: 10